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Inducible Nitric Oxide Synthase in Skeletal Muscle of Patients With
Chronic Heart Failure
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Objectives. The expression and localization of inducible nitric
oxide (NO) synthase (NOS II) was evaluated as a source of NO
which has been shown to affect muscle contraction.
Background. Advanced stages of chronic heart failure are
associated with systemic activation of cytokines which have been
shown to stimulate the expression of NOS II in various cell types,
including myocytes. We hypothesized that systemic cytokine acti-
vation could lead to expression of NOS II in skeletal muscle of
patients with chronic heart failure.
Methods. Skeletal muscle specimens were obtained by percuta-
neous needle biopsy in six normal volunteers and eight patients
with heart failure (New York Heart Association class III). Elec-
tron microscopy immunocytochemistry (immunogold labeling)
with specific anti-NOS antibodies was utilized to elucidate the
intracellular localization of NOS II and neuronal NO synthase
(NOS I) in myocytes of skeletal muscle. Reverse transcriptase,
competitive polymerase chain reaction (PCR) was applied to
quantify NOS II mRNA in skeletal muscle.
Results. Inducible nitric oxide synthase was readily expressed
in the cytosol of skeletal muscle myocytes; NOS I expression was
sparse. Polymerase chain reaction results indicated that NOS II
gene expression is increased in patients with chronic heart failure.
Conclusions. Inducible NO synthase is expressed in human
skeletal muscle and its gene expression is increased in patients
with severe heart failure. Given the experimental evidence that
NO can attenuate contractile performance of skeletal muscle and
can mediate muscle wasting, an increased local production of NO
in skeletal muscle by NOS II may have important implications for
patients with severe heart failure.
(J Am Coll Cardiol 1998;32:964–9)
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Nitric oxide (NO) is an important signaling molecule that
mediates a variety of essential physiologic processes, including
neurotransmission and neuromodulation, vasodilatation and
host cell defense (1). Alterations in NO production have been
implicated in various pathophysiologic processes, such as ath-
erosclerosis, heart failure, hypotension and organ failure asso-
ciated with septic shock (1,2).
Nitric oxide is synthesized from L-arginine by NO synthases
(NOS), a family of isoenzymes with distinct functional, bio-
chemical and regulatory properties (1,3). Both the neuronal
NOS I and the endothelial NOS III are constitutive isoforms
and are discretely expressed in specific tissues. They rapidly
transduce signaling events in a calcium-dependent manner.
While NOS I occurs in a variety of cell types, including
neurons, epithelial cells, mesangial cells and skeletal muscle
cells, NOS III is expressed predominantly in the endothelium
and its activity accounts for endothelium-dependent vascular
relaxation. In contrast to these calcium-dependent enzymes,
the inducible calcium-independent NOS II is expressed in
immunologically activated cells, that is, in response to cyto-
kines such as tumor necrosis factor (TNF)-a, interferon
gamma and certain interleukins.
Advanced stages of chronic heart failure (CHF) are often
associated with systemic and cardiac cytokine activation (4)
and expression of NOS II in the myocardium (5). Recently, it
has been demonstrated that skeletal muscle expresses NOS II
and that this expression can be stimulated with endotoxin (6).
Therefore, it is hypothesized that systemic cytokine activation
could stimulate the expression of NOS II in skeletal muscle of
patients with CHF. Accordingly, the present study examined
the expression of NOS II in skeletal muscle of healthy volun-
teers and patients with CHF.
Methods
Patients. Human skeletal muscle was obtained from six
healthy volunteers (age 44 6 4 years) and eight patients with
CHF (age 52 6 7) after informed consent. The study was
approved by the Ethical Committee of the University of
Freiburg. Volunteers had normal physical examination and
peak oxygen consumption (33 6 2 ml/min/kg) and did not take
any medication. All patients were in New York Heart Associ-
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ation functional class III heart failure and demonstrated
impaired exercise capacity (peak oxygen consumption 14 6
2 ml/min/kg) and ejection fraction (25% 6 3%). All patients
were treated with digoxin, diuretics and angiotensin-converting
enzyme (ACE)-inhibitors. Percutaneous needle biopsies were
obtained from the middle part of the vastus lateralis muscle
under local anesthesia using the Bergstro¨m technique (7) as
established in our laboratory (8).
Reverse transcriptase (RT) polymerase chain reaction
(PCR). Total cellular RNA was isolated from frozen tissue
(9). The amount of RNA was evaluated by spectrophotometry.
The integrity of the RNA was verified by gel electrophoresis.
Quantification of NOS II mRNA was performed by competi-
tive RT-PCR in the presence of a defined concentration of a
shortened NOS II competitor RNA that served as an internal
standard, as previously described (10). The NOS II competitor
template (314 bp) was obtained from a 419-bp cDNA fragment
of the human NOS II cDNA (11) using appropriate restriction
enzymes. Equal amounts of total RNA (2 mg) were mixed with
increasing quantities of competitor (12.5 to 6.25 3 104 mole-
cules). Random hexanucleotide primers and Moloney murine
leukemia virus reverse transcriptase were used to synthesize
complementary DNA. The RT reactions (total volume 25 ml)
were performed at 42°C for 60 min. Sense and antisense
primer oligonucleotides were selected from the human cDNA
sequences of NOS II (11) (sense positions: 1614 to 1633,
59-GGGAGCATCACCCCCGTGTT-39, antisense primer po-
sitions: 2012 to 2033; 59-GAGCGATTTCTTCAGTTTCTCT-
39. Duplicate samples of PCR reaction were performed. De-
naturing, annealing and extension reactions proceeded 36
times at 94°C for 1 min, 62°C for 2 min and 72°C for 3 min. As
a negative control, no amplification product occurred if reverse
transcriptase or total RNA were omitted in the first-strand
cDNA reaction. The PCR products of NOS II mRNA had the
expected size as shown by gel electrophoresis and the specific-
ity of the amplified products was confirmed by restriction
enzyme analysis and by hybridization with specific internal
oligonucleotide probes. After electrophoresis of the PCR
products and staining with ethidium bromide, the bands were
photographed under ultraviolet transillumination. Densito-
metric analysis was performed with photographic negatives. To
correct for differences in size of target and competitor PCR
products, the band densities of the respective competitor PCR
products were multiplied by the specific factor (1.33). The ratio
of competitor to target products was plotted against the
number of competitor molecules on a log scale. At the
competition equivalence point (log ratio 5 0) the original
number of target mRNAs corresponds to the initial number of
competitor RNA molecules used (see Fig. 1). In control
experiments the optimal amount of total RNA and PCR cycle
profile was determined. In one volunteer and one patient each,
only duplicate determinations of NOS II mRNA were per-
formed because the amount of extracted RNA did not allow
multiple RT-PCRs with different concentrations of internal
standard.
Electron microscopy (EM) immunocytochemistry. Muscle
biopsies were fixed in PLP (0.5% glutaraldehyde, 5% parafor-
maldehyde in 0.1M Na-phosphate buffer, 0.2M Lysin-HCl,
0.01 M Na-metaperjodate, pH 7.3) at 4°C for 30 min and then
minced into 1 mm pieces and postfixed for 3.5 h in PLP,
followed by 33 rinsing in PBS-buffer and 4 3 15 min incuba-
tion in NH4Cl 50 mM as detergent. After 103 rinsing in PBS 1
2% saccharose overnight, specimens were dehydrated in dim-
ethylformamid and embedded in Lowicryl using the quick
method of Altman et al. (12). This allows the detection of
immunohistochemical reaction products without dislocation
due to dehydration. The immunohistochemical analysis was
performed on ultrathin sections mounted on formvar-coated
nickel grids. For the immunohistochemical incubation, an
anti-NOS I polyclonal antibody (13) (diluted 1:20) or an
anti-NOS II polyclonal antibody (14) (diluted 1:7.5) and a
rabbit nonimmune IgG (2.5 mg/ml) as a control were used,
each in PBS 1 0.5% BSA 1 1.5% normal goat serum and
BSAc (Aurion) 1:10. Western blot data (15) have demon-
strated that the anti-NOS I antibody recognizes both the
essential NOS I and the recently described splice variant NOS
I-m (16) that is primarily expressed in skeletal muscle. Sections
were incubated in blocking serum (PBS 1 0.5% BSA 1 5%
normal goat serum 1 BSAc 1:10) for 25 min. Incubation of
grids was performed in the first antibody solution overnight at
4°C, then 1 h at room temperature followed by intense rinsing
with incubation buffer. The secondary antibody (IgG gold-
goat-anti rabbit 1:100) containing Tween 20 (1 ml Tween 1
2 ml buffer) was incubated for 2 h at room temperature
followed by intense rinsing. Tissues were fixed for 5 min in 2%
glutaraldehyde in PBS, followed by rinsing with PBS. Staining
was performed for 30 min in 2% uranyl acetate dissolved in
water and lead citrate.
Statistical analysis. Data are mean 6 SEM. Comparisons
between controls and patients with heart failure (mRNA
transcripts) were performed by unpaired t-test.
Results
NOS II mRNA in human skeletal muscle. Reverse
transcription-polymerase chain reaction analysis demonstrated
low levels of NOS II mRNA in skeletal muscle of normal
volunteers. In patients with heart failure, NOS II mRNA levels
were increased (Fig. 2). The increase in NOS II mRNA was
Abbreviations and Acronyms
CHF 5 chronic heart failure
EM 5 electron microscopy
NO 5 nitric oxide
NOS 5 NO synthase
NOS I 5 neuronal nitric oxide synthase
NOS II 5 inducible nitric oxide synthase
PCR 5 polymerase chain reaction
RT 5 reverse transcriptase
TNF 5 tumor necrosis factor
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observed both in patients with dilated (n 5 5) and ischemic
(n 5 3) cardiomyopathy and the expression levels did not
correlate with duration of heart failure; however, the number
of patients was too small to exclude that these and other
factors may affect NOS II gene expression. Angiotensin-
converting enzyme mRNA in these biopsy specimens was
determined using a previously established competitive PCR
(10) and did not reveal differences between normal volunteers
and patients with heart failure. (27.4 6 12.7 104 vs. 26.2 6 15.6
transcripts per 100 ng total RNA).
EM immunocytochemical localization of NOS II and NOS
I in human skeletal muscle. Anti-NOS II antibody-coupled
immunogold particles were localized in the sarcoplasma of
skeletal muscle cells, predominantly over myofibrils (Fig. 3A).
Anti-NOS I antibody-coupled immunogold particles were ob-
served scarcely over the sarcolemma of skeletal muscle cells
(Fig. 3B). In control sections (using canine IgG instead of
primary antibody) no immunogold particles were found (Fig.
3C). Immunogold staining did not allow quantification of NOS
II protein. Therefore, significant differences between NOS II
expression between normal volunteers and patients with heart
failure could not be established. The relative abundance of
NOS II may vary according to the skeletal muscle fiber type
studied (6) which cannot be identified by immunogold EM
staining. Only skeletal muscle cells and capillary endothelium
was visualized in our sections (rather than arterioles). Endo-
thelial cells of capillaries did not show any immunogold
staining with the anti-NOS II of anti-NOS I antibodies.
Discussion
The present study demonstrates expression of NOS II mRNA
and protein in human skeletal muscle.
While the EM immunocytochemical localization of NOS II
in human skeletal muscle did not allow quantification of NOS
II expression within skeletal muscle, the RT-PCR results
suggest that NOS II gene expression is increased in patients
with severe CHF, at an advanced stage of the disease, when
systemic cytokine activation is likely to occur (4). These
Figure 1. NOS II mRNA quantification by competitive RNA-PCR. A
constant amount of total RNA was mixed with an increasing number of
NOS II-competitor RNA molecules, reverse transcribed into cDNA
and amplified in duplicate samples by PCR. The PCR products,
indicated as NOS II target (419 bp) and NOS II competitor (315 bp),
were separated by gel electrophoresis, stained with ethidium bromide
and visualized by UV irradiation. The band densities of NOS II target
and competitor DNA were determined. The mean value of duplicate
samples were plotted as logarithm of the ratio of competitor to gene
target PCR products vs. the logarithm of the known number of
competitor molecules. At the competition equivalence point (log
ratio 5 0) the original number of target mRNAs corresponds to the
initial number of competitor RNA molecules used.
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observations extend previous findings demonstrating NOS II
expression in the myocardium of patients with heart failure (5).
Thus, it appears that the systemic and/or local cytokine acti-
vation in patients with severe heart failure is associated with
cardiac and increased peripheral expression of NOS II. This
NOS II expression is likely to be a specific event because
mRNA level for ACE in human skeletal muscle showed no
difference between normal subjects and CHF patients.
Recent evidence suggests the expression of NOS II also in
response to signals that are noninflammatory, nonimmuno-
logic or unapparent (17–19). However, in contrast to NOS II
expression in normal lung epithelial cells or nephron cells
(18,19), exposure of skeletal muscle myocytes to bacteria
appears unlikely. The present finding that NOS II is consti-
tutively expressed in human skeletal muscle of control
subjects is consistent with recent observations by Park et al.
(20). Similar observations have been made in specific
pathogen-free guinea pigs and have been associated with
functional consequences in these animals (6). The underly-
ing mechanisms for the expression of NOS II in normal
skeletal muscle remains to be determined. However, evi-
dence has recently been presented that normal human
skeletal muscle expresses TNF-a (21). Whether other cyto-
kines are expressed by normal human skeletal muscle is
unknown. Nevertheless, this observation raises the possibil-
ity that TNF-a may be involved in the expression of NOS II
in normal skeletal muscle.
We did not detect NOS II expression in endothelial cells of
capillaries. Due to the small size of tissues prepared for EM
(containing only skeletal muscle tissue), no arterioles with
vascular smooth muscle cells or macrophages were visualized
in the sections investigated. Thus, we cannot exclude the
possibility that NOS II expression occurs in these cell types,
particularly in patients with heart failure. Indeed, the en-
hanced vasoconstrictor response following the inhibition of
NO-synthesis by N-methyl-L-arginine would be consistent with
the notion that severe heart failure is associated with expres-
sion of NOS II in the vascular wall of peripheral resistance
vessels (22).
Neuronal nitric oxide synthase was the first isoform to be
identified in skeletal muscle (23). Its distribution within muscle
tissue is still somewhat controversial. Kobzik et al. (23) re-
ported that NOS I in rat skeletal muscle was restricted to type
Figure 2. NOS II mRNA levels (transcripts/mg RNA) in normal
volunteers (control) and patients with CHF.
Figure 3. Electron microscopy immunogold-labeling using anti-NOS
II antibody (A), anti-NOS I antibody (B) and control (C) of skeletal
muscle in a patient with heart failure. Note the numerous small black
dots grouped over myofibrils using anti-NOS II antibody while staining
with these dots is scarce with anti-NOS I antibody and absent in
control.
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II fibers (fast-twitch) whereas type I fibers (slow-twitch inter-
mediate fibers) were NOS I negative. However, in a recent
study by Brennan et al. (24), fibers from the quadriceps muscle
of normal mice were all NOS I positive, whereas no staining
was seen in muscle of NOS I knockout mice. We have
demonstrated previously that, by far, the highest expression of
NOS I in guinea pig skeletal muscle is in the neuromuscular
endplate (6). This regional distribution of NOS I may explain
the low abundance of immunogold staining in our EM
immunocytochemical analysis which cannot identify neuro-
muscular structures. Endothelial nitric oxide synthase ex-
pression has also been demonstrated in skeletal muscle (25),
although the expression level seems to be relatively low (6).
Our present observation together with previous experimen-
tal studies (6,23,25) suggest that all three isoforms of NOS
may be present in distinct structures and/or fiber types of
skeletal muscle.
Limitations of the present study. Some limitations need to
be addressed. First, the skeletal muscle biopsy may have
contained trace amounts of blood vessels and blood cells which
could have contributed to the increased NOS II mRNA levels
observed in CHF patients. The present approach cannot
exclude the contribution of NOS II gene expression in vascular
smooth muscle cells. However, provided that the increased
NOS II mRNA levels in CHF are translated into increased
NOS activity, the enhanced NO derived from either source
(smooth muscle cell or skeletal muscle) may affect both
vasomotor tone and skeletal muscle function in a autocrine or
paracrine fashion. Trace amounts of erythrocytes, platelets
and/or leukocytes are likely to be included in skeletal muscle
biopsies. However, it appears unlikely that these “contaminat-
ing cells” account for the fourfold to fivefold increase in NOS
II mRNA levels in CHF. We did not detect NOS II mRNA in
leukocytes obtained from two CHF patients who expressed
NOS II mRNA in their skeletal muscle specimens. Further-
more human neutrophils have recently been shown to express
NOS I but no NOS II (26). Furthermore NOS II protein has
been detected in skeletal muscle of CHF patients (Fig. 3A),
suggesting that the NOS II mRNA is likely to derive from the
same cellular source.
Potential functional implications. The expression of NOS
II in skeletal muscle may have important functional conse-
quences. Nitric oxide rapidly and reversibly inhibits the
steady-state turnover of isolated cytochrome oxidase at
submicromolar concentrations. The inhibition of cyto-
chrome oxidase is competitive with oxygen, and NO binds
with high affinity to the oxygen-binding site of cytochrome
oxidase when its site is reduced (27). Inhibition of this
enzyme may cause decreased ATP production and increases
the cellular levels of ADP, AMP, GDP and Pi, which
regulate a large range of cellular processes, including mus-
cle contraction. Indeed, NO has been shown to attenuate
the contractile performance of skeletal muscle (6,23) and to
inhibit oxygen consumption (28).
Beyond the regulation of contractile force, NO may have
important long-term implications in skeletal muscle. There is
evidence that oxidative stress pathways interact with NO to
modulate cytoprotective or cytotoxic effects (29). More
recently, Buck and Chojkier (30) demonstrated that NOS
activity of skeletal muscle mediates effects of oxidative stress
on muscle dedifferentiation and muscle wasting. These
observations may have important implications given the
notion that NOS II expression is increased in patients with
severe CHF and the evidence for muscle wasting in this
setting (31), that is, enhanced local production of NO by
NOS II following cytokine activation may be involved in
muscle wasting of patients with advanced stages of heart
failure and cachexia.
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